SG10201900886RA - Methods and therapeutic combinations for treating tumors - Google Patents

Methods and therapeutic combinations for treating tumors

Info

Publication number
SG10201900886RA
SG10201900886RA SG10201900886RA SG10201900886RA SG10201900886RA SG 10201900886R A SG10201900886R A SG 10201900886RA SG 10201900886R A SG10201900886R A SG 10201900886RA SG 10201900886R A SG10201900886R A SG 10201900886RA SG 10201900886R A SG10201900886R A SG 10201900886RA
Authority
SG
Singapore
Prior art keywords
methods
therapeutic combinations
treating tumors
effective amount
therapeutically effective
Prior art date
Application number
SG10201900886RA
Inventor
John Vasilakos
Willem Overwijk
Original Assignee
3M Innovative Properties Co
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co, Univ Texas filed Critical 3M Innovative Properties Co
Publication of SG10201900886RA publication Critical patent/SG10201900886RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Abstract

METHODS AND THERAPEUTIC COMBINATIONS FOR TREATING TUMORS 5 Methods and therapeutic combinations useful for increasing cell-mediated anti-tumor responses are described. The methods include administering to a subject a therapeutically effective amount of an Immune Response Modifier Compound and a therapeutically effective amount of one or more immune checkpoint inhibitor compounds. 10 [Fig. 1]
SG10201900886RA 2014-08-01 2015-07-31 Methods and therapeutic combinations for treating tumors SG10201900886RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462032149P 2014-08-01 2014-08-01

Publications (1)

Publication Number Publication Date
SG10201900886RA true SG10201900886RA (en) 2019-03-28

Family

ID=55218348

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201700700YA SG11201700700YA (en) 2014-08-01 2015-07-31 Methods and therapeutic combinations for treating tumors
SG10201900886RA SG10201900886RA (en) 2014-08-01 2015-07-31 Methods and therapeutic combinations for treating tumors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201700700YA SG11201700700YA (en) 2014-08-01 2015-07-31 Methods and therapeutic combinations for treating tumors

Country Status (13)

Country Link
US (2) US9980956B2 (en)
EP (1) EP3174538B1 (en)
JP (1) JP6666343B2 (en)
KR (1) KR102540008B1 (en)
CN (1) CN107106545B (en)
AU (1) AU2015296214B2 (en)
CA (1) CA2956717A1 (en)
EA (1) EA201790180A1 (en)
IL (1) IL250172A0 (en)
MX (1) MX2017001154A (en)
SG (2) SG11201700700YA (en)
WO (1) WO2016019232A1 (en)
ZA (1) ZA201701491B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014347059B2 (en) * 2013-11-05 2017-09-07 Solventum Intellectual Properties Company Sesame oil based injection formulations
US9980956B2 (en) * 2014-08-01 2018-05-29 3M Innovative Properties Company Methods and therapeutic combinations for treating tumors
AR109629A1 (en) * 2016-09-08 2019-01-09 Medimmune Llc COMPOSITIONS FOR THE LOCAL ADMINISTRATION OF TOLL TYPE RECEIVER AGONISTS
SG10201914029RA (en) 2016-10-14 2020-03-30 Precision Biosciences Inc Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
AR111760A1 (en) 2017-05-19 2019-08-14 Novartis Ag COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS THROUGH INTRATUMORAL ADMINISTRATION
WO2019117132A1 (en) * 2017-12-12 2019-06-20 地方独立行政法人神奈川県立病院機構 Biomarker for prognostic prediction of cancer immunotherapy
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CA3084569A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
RU2020124007A (en) * 2017-12-21 2022-01-21 Сумитомо Дайниппон Фарма Ко., Лтд. COMBINATION DRUG INCLUDING TLR7 AGONIST
CN111788204B (en) 2018-02-26 2023-05-05 吉利德科学公司 Substituted pyrrolizine compounds as inhibitors of HBV replication
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TWI818007B (en) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-cyclic dinucleotides
TW202005654A (en) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2'2'-cyclic dinucleotides
EP3774832A1 (en) 2018-04-06 2021-02-17 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotides
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
AU2018101488A4 (en) * 2018-10-05 2018-11-08 Macau University Of Science And Technology Method and kit for treating cancer through combination therapy
SG11202103839UA (en) 2018-10-31 2021-05-28 Gilead Sciences Inc Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
TW202136261A (en) 2018-10-31 2021-10-01 美商基利科學股份有限公司 Substituted 6-azabenzimidazole compounds
KR20210137517A (en) 2019-03-07 2021-11-17 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 2'3'-cyclic dinucleotides and prodrugs thereof
KR20210137518A (en) 2019-03-07 2021-11-17 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
TW202212339A (en) 2019-04-17 2022-04-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TW202210480A (en) 2019-04-17 2022-03-16 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TWI826690B (en) 2019-05-23 2023-12-21 美商基利科學股份有限公司 Substituted eneoxindoles and uses thereof
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US11497808B2 (en) 2019-09-30 2022-11-15 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
CN116057068A (en) 2019-12-06 2023-05-02 精密生物科学公司 Optimized engineered meganucleases with specificity for recognition sequences in hepatitis b virus genomes
CN115605493A (en) 2020-03-20 2023-01-13 吉利德科学公司（Us） Prodrugs of4'-C-substituted-2-halo-2' -deoxyadenosine nucleosides and methods of making and using the same
CN112494645A (en) * 2020-12-09 2021-03-16 南京大学 Application of arsenic alkene nano material and immune checkpoint inhibitor in tumor treatment in combination
JP2024518558A (en) 2021-05-13 2024-05-01 ギリアード サイエンシーズ， インコーポレイテッド Combination of TLR8 Modulating Compounds with Anti-HBV siRNA Therapeutics
WO2022261310A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
CA3222269A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
KR20240023628A (en) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 Diacylglycerol Kinase Modulating Compounds
CN117355531A (en) 2021-06-23 2024-01-05 吉利德科学公司 Diacylglycerol kinase modulating compounds
KR20240025616A (en) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 Diacylglycerol Kinase Modulating Compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
WO2005055932A2 (en) * 2003-12-02 2005-06-23 3M Innovative Properties Company Therapeutic combinations and methods including irm compounds
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
CN101443005A (en) * 2004-12-30 2009-05-27 科勒制药集团公司 Immune response modifier formulations and methods
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
US8242106B2 (en) * 2008-08-01 2012-08-14 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
EP3222621B1 (en) * 2010-08-17 2023-03-08 3M Innovative Properties Company Lipidated immune response modifier compound and its medical use
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
WO2014201245A1 (en) 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
BR112016001420A2 (en) * 2013-08-02 2018-01-23 Aduro Biotech Holdings Europe B V cd27 agonist combination and immune point inhibition for immune stimulation
US9980956B2 (en) * 2014-08-01 2018-05-29 3M Innovative Properties Company Methods and therapeutic combinations for treating tumors
CN116059218A (en) * 2015-07-16 2023-05-05 比奥克斯塞尔医疗股份有限公司 Novel method for treating cancer using immunomodulation

Also Published As

Publication number Publication date
EP3174538A4 (en) 2018-02-28
EA201790180A1 (en) 2017-07-31
EP3174538B1 (en) 2019-11-06
CA2956717A1 (en) 2016-02-04
JP6666343B2 (en) 2020-03-13
IL250172A0 (en) 2017-03-30
US9980956B2 (en) 2018-05-29
KR20170040260A (en) 2017-04-12
US10583134B2 (en) 2020-03-10
BR112017001974A2 (en) 2017-11-21
ZA201701491B (en) 2022-05-25
MX2017001154A (en) 2017-11-30
US20170216276A1 (en) 2017-08-03
SG11201700700YA (en) 2017-02-27
WO2016019232A1 (en) 2016-02-04
KR102540008B1 (en) 2023-06-02
EP3174538A1 (en) 2017-06-07
AU2015296214A1 (en) 2017-02-16
CN107106545B (en) 2020-05-19
US20180243287A1 (en) 2018-08-30
AU2015296214B2 (en) 2019-11-07
JP2017523244A (en) 2017-08-17
CN107106545A (en) 2017-08-29

Similar Documents

Publication Publication Date Title
SG10201900886RA (en) Methods and therapeutic combinations for treating tumors
MX2022003895A (en) Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome.
MX2021013837A (en) Combination immunotherapy approach for treatment of cancer.
MX2019005465A (en) Immunotherapeutic tumor treatment method.
MX2021004881A (en) Methods of treating cancer.
ZA201804513B (en) Method of treating c3 glomerulopathy
MX2018006674A (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor.
MX2018008426A (en) Anti-egfr combinations for treating tumors.
MX2017002824A (en) Inhibitors of lysine specific demethylase-1.
MX2018008427A (en) Anti-cd20 combinations for treating tumors.
MX2017000179A (en) Inhibitors of lysine specific demethylase-1.
MX2020010900A (en) Inhibitors of lysine specific demethylase-1.
MX2018001755A (en) Smallpox vaccine for use in cancer treatment.
MX2017000170A (en) Inhibitors of lysine specific demethylase-1.
MX2018003893A (en) Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough.
EA036102B9 (en) Glycotargeting therapeutics
MX2017006464A (en) Tlr inhibitor and bruton's tyrosine kinase inhibitor combinations.
IL282007A (en) Medicament for the treatment of chronic cough
MY201580A (en) Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor
AU2016282877A8 (en) Antibodies against human CSF-1R for use in inducing lymphocytosis in lymphomas or leukemias
MX2016016388A (en) Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds.
EP3888648A4 (en) Treatment of cancer by combination of immune checkpoint inhibitor and folfirinox therapy
EA201890868A1 (en) BACTERIA WITH FACED VIRULENCE FOR THE TREATMENT OF MALIGNANT SOLID TUMORS
WO2016094899A3 (en) Treatment of hmgb1-mediated inflammation
EP3302557A4 (en) Enhancing the therapeutic activity of an immune checkpoint inhibitor